A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Equinoxe Humeral Augmented Tray: 1st Shoulder Surgeries with New Solution for Proximal Humeral Bone Loss Performed in Florida

March 29, 2021

The Equinoxe Humeral Augmented Tray is the first implant of its kind. It replaces the greater tuberosity, a part of the shoulder that may be absent or deficient, fractured and/or reabsorbed due to disease.

The HAT was designed to be used in combination with the Equinoxe Platform Shoulder System for reverse procedures and was designed to help improve joint mechanics and stability for patients with proximal humeral bone loss. This unique implant can also be used with an extension for more severe proximal bone loss cases.

The first surgeries with the Humeral Augmented Tray were performed last week in Florida by Bradley Schoch, MD, of the Mayo Clinic in Jacksonville, and design team surgeon Howard Routman, DO, of JFK Medical Center in Lantana.

“The patients who need this implant have either previously undergone surgeries which failed, suffered fractures of the humeral head, or have congenital abnormalities that leave them with deficient tuberosities, which prevent them from doing what they want,” said Dr. Routman. “This implant allows them to return to what they love, and I feel very honored to have been part of the design team and one of the first to use this prosthesis.”

“We are very pleased to launch the Humeral Augmented Tray and excited to receive feedback from our surgeon colleagues and see its impact on patients. Its addition to the Equinoxe Shoulder family allows us to reach even more patients,” said Vice President of Extremities Chris Roche.

The design team includes Dr. Routman, Thomas Wright, MD, of the University of Florida in Gainesville, Fla.; Pierre-Henri Flurin, MD, of Surgical Clinic of Bordeaux in Merginac, France; Matthew Hansen, MD, of Banner Gateway Medical Center in Gilbert, Ariz.; Raymond Klug, MD, of Lakewood Regional Medical Center in Lakewood, Calif.; and Joseph D. Zuckerman, MD, of NYU Langone Orthopedic Hospital in New York City.

 

SourceExactech
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy